esomeprazole
esomeprazole: 9 clinical trials tracked.
esomeprazole evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about esomeprazole, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 7 study sponsors
Related indications
Clinical Trials (9)
Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU (EPIC-ICU)
Primary endpoint: Proportion of time intragastric pH ≥4 during the 72 hours post dosing
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734
A Phase 1, Open-Label, 4-Part Trial to Assess the Drug-Drug Interaction Between Zasocitinib and Combined Oral Contraceptives, a MATE Substrate, a P-gp Substrate, and a Proton-Pump Inhibitor in Healthy Participants
Primary endpoint: Part 1: Cmax: Maximum Observed Plasma Concentration for LNG and EE When Administered Alone and With Zasocitinib
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules
Primary endpoint: Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose-Escalation, Drug-Interaction, and Food-Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participants
Primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs)
A PHASE 1, OPEN-LABEL, 2-PERIOD STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF ESOMEPRAZOLE ON THE PHARMACOKINETICS OF SINGLE DOSE VEPDEGESTRANT (ARV-471, PF-07850327) UNDER THE FED CONDITION IN HEALTHY ADULT MALES AND HEALTHY ADULT FEMALES OF NONCHILDBEARING POTENTIAL
Primary endpoint: Maximum observed plasma concentration (Cmax) of vepdegestrant when vepdegestrant is administered alone
A Phase 1, Open Label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib When Administered Alone and With Multiple Doses of Rifampin (CYP3A Inducer) or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects
Primary endpoint: Parts 1 and 2: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970
Primary endpoint: Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
An Open-Label Pilot Study of Esomeprazole in Children With Autism
Primary endpoint: Change from Baseline on the Social Responsiveness Scale, 2nd Edition (SRS-2)